Edward J Schenck1,2, Kevin C Ma3, David R Price1,2, Thomas Nicholson2, Clara Oromendia4, Eliza Rose Gentzler1, Elizabeth Sanchez1, Rebecca M Baron5, Laura E Fredenburgh5, Jin-Won Huh6, Ilias I Siempos1,7, Augustine Mk Choi1,2. 1. Division of Pulmonary and Critical Care Medicine, Joan and Sanford I. Weill Department of Medicine, Weill Cornell Medicine, New York, New York, USA. 2. New York-Presbyterian Hospital Weill Cornell Medical Center, New York, New York, USA. 3. Section of Interventional Pulmonology and Thoracic Oncology, Division of Pulmonary, Allergy and Critical Care, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA. 4. Department of Healthcare Policy and Research, Division of Biostatistics and Epidemiology, Weill Cornell Medicine, New York, New York, USA. 5. Division of Pulmonary and Critical Care Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA. 6. Department of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine, Ulsan, South Korea. 7. First Department of Critical Care Medicine and Pulmonary Services, Evangelismos Hospital, University of Athens Medical School, Athens, Greece.
Abstract
BACKGROUND: In sepsis, there may be dysregulation in programed cell death pathways, typified by apoptosis and necroptosis. Programmed cell death pathways may contribute to variability in the immune response. TRAIL is a potent inducer of apoptosis. Receptor-interacting serine/threonine protein kinase-3 (RIPK3) is integral to the execution of necroptosis. We explored whether plasma TRAIL levels were associated with in-hospital mortality, organ dysfunction, and septic shock. We also explored the relationship between TRAIL and RIPK3. METHODS: We performed an observational study of critically ill adults admitted to intensive care units at 3 academic medical centers across 2 continents, using 1 as derivation and the other 2 as validation cohorts. Levels of TRAIL were measured in the plasma of 570 subjects by ELISA. RESULTS: In all cohorts, lower (<28.5 pg/ml) versus higher levels of TRAIL were associated with increased organ dysfunction (P ≤ 0.002) and septic shock (P ≤ 0.004). Lower TRAIL levels were associated with in-hospital mortality in 2 of 3 cohorts (Weill Cornell-Biobank of Critical Illness, P = 0.012; Brigham and Women's Hospital Registry of Critical Illness, P = 0.011; Asan Medical Center, P = 0.369). Lower TRAIL was also associated with increased RIPK3 (P ≤ 0.001). CONCLUSION: Lower levels of TRAIL were associated with septic shock and organ dysfunction in 3 independent ICU cohorts. TRAIL was inversely associated with RIPK3 in all cohorts. FUNDING: NIH (R01-HL055330 and KL2-TR002385).
BACKGROUND: In sepsis, there may be dysregulation in programed cell death pathways, typified by apoptosis and necroptosis. Programmed cell death pathways may contribute to variability in the immune response. TRAIL is a potent inducer of apoptosis. Receptor-interacting serine/threonine protein kinase-3 (RIPK3) is integral to the execution of necroptosis. We explored whether plasma TRAIL levels were associated with in-hospital mortality, organ dysfunction, and septic shock. We also explored the relationship between TRAIL and RIPK3. METHODS: We performed an observational study of critically ill adults admitted to intensive care units at 3 academic medical centers across 2 continents, using 1 as derivation and the other 2 as validation cohorts. Levels of TRAIL were measured in the plasma of 570 subjects by ELISA. RESULTS: In all cohorts, lower (<28.5 pg/ml) versus higher levels of TRAIL were associated with increased organ dysfunction (P ≤ 0.002) and septic shock (P ≤ 0.004). Lower TRAIL levels were associated with in-hospital mortality in 2 of 3 cohorts (Weill Cornell-Biobank of Critical Illness, P = 0.012; Brigham and Women's Hospital Registry of Critical Illness, P = 0.011; Asan Medical Center, P = 0.369). Lower TRAIL was also associated with increased RIPK3 (P ≤ 0.001). CONCLUSION: Lower levels of TRAIL were associated with septic shock and organ dysfunction in 3 independent ICU cohorts. TRAIL was inversely associated with RIPK3 in all cohorts. FUNDING: NIH (R01-HL055330 and KL2-TR002385).
Authors: Linde Duprez; Nozomi Takahashi; Filip Van Hauwermeiren; Benjamin Vandendriessche; Vera Goossens; Tom Vanden Berghe; Wim Declercq; Claude Libert; Anje Cauwels; Peter Vandenabeele Journal: Immunity Date: 2011-12-23 Impact factor: 31.745
Authors: Katharina Cziupka; Alexandra Busemann; Lars Ivo Partecke; Christian Pötschke; Matthias Rath; Tobias Traeger; Pia Koerner; Wolfram von Bernstorff; Wolfram Kessler; Stephan Diedrich; Frank Ulrich Weiss; Stefan Maier; Barbara M Bröker; Claus-Dieter Heidecke Journal: Crit Care Med Date: 2010-11 Impact factor: 7.598
Authors: Tamás Dolinay; Young Sam Kim; Judie Howrylak; Gary M Hunninghake; Chang Hyeok An; Laura Fredenburgh; Anthony F Massaro; Angela Rogers; Lee Gazourian; Kiichi Nakahira; Jeffrey A Haspel; Roberto Landazury; Sabitha Eppanapally; Jason D Christie; Nuala J Meyer; Lorraine B Ware; David C Christiani; Stefan W Ryter; Rebecca M Baron; Augustine M K Choi Journal: Am J Respir Crit Care Med Date: 2012-03-29 Impact factor: 21.405
Authors: Edith M Janssen; Nathalie M Droin; Edward E Lemmens; Michael J Pinkoski; Steven J Bensinger; Benjamin D Ehst; Thomas S Griffith; Douglas R Green; Stephen P Schoenberger Journal: Nature Date: 2005-03-03 Impact factor: 49.962
Authors: Kathrin Steinwede; Stefanie Henken; Jennifer Bohling; Regina Maus; Bianca Ueberberg; Christina Brumshagen; Erik L Brincks; Thomas S Griffith; Tobias Welte; Ulrich A Maus Journal: J Exp Med Date: 2012-10-15 Impact factor: 14.307
Authors: Karsten Suhre; Hina Sarwath; Rudolf Engelke; Muhammad Umar Sohail; Soo Jung Cho; William Whalen; Sergio Alvarez-Mulett; Jan Krumsiek; Augustine M K Choi; Frank Schmidt Journal: Front Immunol Date: 2022-01-25 Impact factor: 7.561
Authors: David R Price; Elisa Benedetti; Katherine L Hoffman; Luis Gomez-Escobar; Sergio Alvarez-Mulett; Allyson Capili; Hina Sarwath; Christopher N Parkhurst; Elyse Lafond; Karissa Weidman; Arjun Ravishankar; Jin Gyu Cheong; Richa Batra; Mustafa Büyüközkan; Kelsey Chetnik; Imaani Easthausen; Edward J Schenck; Alexandra C Racanelli; Hasina Outtz Reed; Jeffrey Laurence; Steven Z Josefowicz; Lindsay Lief; Mary E Choi; Frank Schmidt; Alain C Borczuk; Augustine M K Choi; Jan Krumsiek; Shahin Rafii Journal: Am J Pathol Date: 2022-04-22 Impact factor: 5.770
Authors: Richa Batra; Rie Uni; Oleh M Akchurin; Sergio Alvarez-Mulett; Luis G Gómez-Escobar; Edwin Patino; Katherine L Hoffman; Will Simmons; Kelsey Chetnik; Mustafa Buyukozkan; Elisa Benedetti; Karsten Suhre; Edward Schenck; Soo Jung Cho; Augustine M K Choi; Frank Schmidt; Mary E Choi; Jan Krumsiek Journal: medRxiv Date: 2022-08-10